PEOPLE - Molecular Insight Pharmaceuticals makes appointment:
This article was originally published in Clinica
Executive Summary
Former deputy commissioner for medical and scientific affairs at the US Centers for Medicare and Medicaid Services (CMS) Scott Gottlieb has become a board member at Molecular Insight Pharmaceuticals. The Cambridge, Massachusetts company will use his regulatory and reimbursement expertise as it develops its pipeline of molecular imaging pharmaceuticals and targeted radiotherapeutics for use in oncology and cardiology.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.